Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 3/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.32 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 3/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.32 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.31 |
| ▸ | SGK1 | O00141 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13870040 | 0.86 | SGK1 (0.32) | ABCB1ABCG2ABCC1TGFBR1IRAK1 | |
| SCHEMBL4016508 | 0.82 | POLB (0.39) | ABCG2SGK1PRKCI | |
| SCHEMBL4018990 | 0.81 | MAT2A (0.32) | IRAK1 | |
| SCHEMBL4018804 | 0.81 | MAPT (0.38) | — | |
| SCHEMBL4020007 | 0.79 | ABCG2 (0.38) | ABCG2 | |
| SCHEMBL4017115 | 0.79 | GPR39 (0.41) | TGFBR1 | |
| SCHEMBL4021900 | 0.78 | PDE5A (0.42) | ABCG2 | |
| SCHEMBL4026069 | 0.78 | AR (0.37) | CDK2 | |
| SCHEMBL4023848 | 0.78 | NPC1 (0.37) | IRAK1 | |
| SCHEMBL4018995 | 0.76 | IDH2 (0.32) | SGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663241-B1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2009-05-27 | — | — | EP | claimed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | claimed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | claimed |
| EP-1663241-B1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | DPYD, ABCC1, ARF5 | ABCB1 5/4885ABCG2 50/4885CDK2 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.